Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival.
Sobral-Leite M, Van de Vijver K, Michaut M, van der Linden R, Hooijer GKJ, Horlings HM, Severson TM, Mulligan AM, Weerasooriya N, Sanders J, Glas AM, Wehkamp D, Mittempergher L, Kersten K, Cimino-Mathews A, Peters D, Hooijberg E, Broeks A, van de Vijver MJ, Bernards R, Andrulis IL, Kok M, de Visser KE, Schmidt MK. Sobral-Leite M, et al. Among authors: mittempergher l. Oncoimmunology. 2018 Sep 11;7(12):e1509820. doi: 10.1080/2162402X.2018.1509820. eCollection 2018. Oncoimmunology. 2018. PMID: 30524905 Free PMC article.
MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology.
Mittempergher L, Delahaye LJMJ, Witteveen AT, Spangler JB, Hassenmahomed F, Mee S, Mahmoudi S, Chen J, Bao S, Snel MHJ, Leidelmeijer S, Besseling N, Bergstrom Lucas A, Pabón-Peña C, Linn SC, Dreezen C, Wehkamp D, Chan BY, Bernards R, van 't Veer LJ, Glas AM. Mittempergher L, et al. J Mol Diagn. 2019 Sep;21(5):808-823. doi: 10.1016/j.jmoldx.2019.04.007. Epub 2019 Jun 4. J Mol Diagn. 2019. PMID: 31173928 Free article.
Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris.
Slembrouck L, Darrigues L, Laurent C, Mittempergher L, Delahaye LJ, Vanden Bempt I, Vander Borght S, Vliegen L, Sintubin P, Raynal V, Bohec M, Reyes C, Rapinat A, Helsmoortel C, Jongen L, Hoste G, Neven P, Wildiers H, Smeets A, Nevelsteen I, Punie K, Van Nieuwenhuysen E, Han S, Vincent Salomon A, Laas Faron E, Cynober T, Gentien D, Baulande S, Snel MH, Witteveen AT, Neijenhuis S, Glas AM, Reyal F, Floris G. Slembrouck L, et al. Among authors: mittempergher l. Transl Oncol. 2019 Dec;12(12):1557-1565. doi: 10.1016/j.tranon.2019.08.008. Epub 2019 Sep 9. Transl Oncol. 2019. PMID: 31513983 Free PMC article.
Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test.
Mittempergher L, Delahaye LJ, Witteveen AT, Snel MH, Mee S, Chan BY, Dreezen C, Besseling N, Luiten EJ; Annuska M Glas. Electronic address: Annuska.Glas@agendia.com. Mittempergher L, et al. Transl Oncol. 2020 Apr;13(4):100756. doi: 10.1016/j.tranon.2020.100756. Epub 2020 Mar 21. Transl Oncol. 2020. PMID: 32208353 Free PMC article.
Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis.
Schlicker A, Ellappalayam A, Beumer IJ, Snel MHJ, Mittempergher L, Diosdado B, Dreezen C, Tian S, Salazar R, Loupakis F, Pietrantonio F, Santos Vivas C, Martinez-Villacampa MM, Villanueva A, Sanjuán X, Schirripa M, Fassan M, Martinetti A, Fucà G, Lonardi S, Keilholz U, Glas AM, Bernards R, Vecchione L. Schlicker A, et al. Among authors: mittempergher l. Int J Cancer. 2020 Oct 15;147(8):2303-2315. doi: 10.1002/ijc.33003. Epub 2020 Apr 24. Int J Cancer. 2020. PMID: 32270478 Free article.
Treatment response and 5-year distant metastasis-free survival outcome in breast cancer patients after the use of MammaPrint and BluePrint to guide preoperative systemic treatment decisions.
Göker E, Hendriks MP, van Tilburg M, Barcaru A, Mittempergher L, van Egmond A, Kleijn M, Generali D; of the NBREaST II Investigators Group. Göker E, et al. Among authors: mittempergher l. Eur J Cancer. 2022 May;167:92-102. doi: 10.1016/j.ejca.2022.03.003. Epub 2022 Apr 11. Eur J Cancer. 2022. PMID: 35421703 Free article.
BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance.
Kuilman MM, Ellappalayam A, Barcaru A, Haan JC, Bhaskaran R, Wehkamp D, Menicucci AR, Audeh WM, Mittempergher L, Glas AM. Kuilman MM, et al. Among authors: mittempergher l. Breast Cancer Res Treat. 2022 Oct;195(3):263-274. doi: 10.1007/s10549-022-06698-x. Epub 2022 Aug 19. Breast Cancer Res Treat. 2022. PMID: 35984580 Free PMC article.
BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer.
Liefaard MC, van der Voort A, van Ramshorst MS, Sanders J, Vonk S, Horlings HM, Siesling S, de Munck L, van Leeuwen AE, Kleijn M, Mittempergher L, Kuilman MM, Glas AM, Wesseling J, Lips EH, Sonke GS. Liefaard MC, et al. Among authors: mittempergher l. Breast Cancer Res. 2023 Jun 19;25(1):71. doi: 10.1186/s13058-023-01664-x. Breast Cancer Res. 2023. PMID: 37337299 Free PMC article.
27 results